查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1970508

全球旅行疫苗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Travel Vaccines Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

旅行疫苗市场预计将从 2025 年的 58.1 亿美元成长到 2034 年的 138.5 亿美元，2026 年至 2034 年的复合年增长率为 10.12%。

随着国际旅行、旅游业的日益繁荣以及全球劳动力的扩张，旅行疫苗市场正稳步成长。旅行疫苗能够预防各地流行的感染疾病，对维护公众健康至关重要。随着公众意识的提高和免疫接种宣传活动的扩大，越来越多的旅客将接种疫苗作为出国旅行前的预防措施。

生物技术创新正在改变市场格局。重组技术、佐剂和无针给药系统的进步正在提高疫苗的有效性、安全性和患者依从性。能够抵御多种病原体的联合疫苗简化了免疫接种程序，尤其对经常旅行的人和医护人员而言更是如此。数位化平台透过预约管理、健康教育和个人化健康建议，进一步提升了疫苗的可近性。

预计未来成长将主要受全球卫生倡议和疫情应对措施的推动。各国政府、非政府组织和私人公司正在增加对疫苗研发、生产和分销基础设施的投资。探险旅游、商务旅行和跨境流动的增加预计将维持强劲的需求。随着生技和数位医疗的融合，旅游疫苗市场可望在保障全球流动性和增强抵抗感染疾病的能力方面发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球旅行疫苗市场：依构成

  • 市场分析、洞察与预测
  • 单剂疫苗
  • 联合疫苗

第五章 全球旅行疫苗市场：依疾病类型划分

  • 市场分析、洞察与预测
  • 甲型肝炎
  • B型肝炎
  • 流感
  • 白喉、百日咳和破伤风（DPT）
  • 狂犬病
  • 黄热病
  • 伤寒
  • 麻疹和腮腺炎
  • 脑膜炎奈瑟菌
  • 其他疾病疫苗

第六章：全球旅行疫苗市场：依应用领域划分

  • 市场分析、洞察与预测
  • 海外旅行
  • 国内旅行

第七章 全球旅行疫苗市场：按地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第八章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第九章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • GSK Plc
    • Sanofi
    • Janssen Pharmaceuticals Inc
    • Pfizer Inc
    • CSL Ltd
    • Qiagen NV
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Valneva Inc
简介目录
Product Code: VMR11217083

The Travel Vaccines Market size is expected to reach USD 13.85 Billion in 2034 from USD 5.81 Billion (2025) growing at a CAGR of 10.12% during 2026-2034.

The travel vaccines market is growing steadily as international mobility, tourism, and global workforce expansion increase. Travel vaccines protect against infectious diseases prevalent in different regions, making them essential for safeguarding public health. With rising awareness and expanding vaccination campaigns, more travelers are prioritizing immunization as a preventive measure before international journeys.

Innovation in biotechnology is reshaping the landscape. Advances in recombinant technology, adjuvants, and needle-free delivery systems are improving efficacy, safety, and patient compliance. Combination vaccines that protect against multiple pathogens are simplifying immunization schedules, particularly for frequent travelers and healthcare workers. Digital platforms are further enhancing vaccine accessibility through scheduling, education, and personalized health recommendations.

Future growth will be driven by global health security initiatives and pandemic preparedness. Governments, NGOs, and private companies are investing in vaccine research, production, and distribution infrastructure. The rise of adventure tourism, corporate travel, and cross-border migration is expected to sustain strong demand. As biotechnology and digital health converge, the travel vaccines market is poised to play an integral role in ensuring global mobility and resilience against infectious diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Composition

  • Mono Vaccines
  • Combination Vaccines

By Disease Type

  • Hepatitis A
  • Hepatitis B
  • Influenza
  • Diphtheria Pertussis Tetanus (DPT)
  • Rabies
  • Yellow Fever
  • Typhoid
  • Measles And Mumps
  • Meningococcal
  • Other Disease Vaccines

By Application

  • Outbound Travel
  • Domestic Travel

COMPANIES PROFILED

  • GSK plc, Sanofi, Janssen Pharmaceuticals Inc, Pfizer Inc, CSL Ltd, Qiagen NV, AstraZeneca, F HoffmannLa Roche Ltd, Abbott Laboratories, Valneva Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL TRAVEL VACCINES MARKET: BY COMPOSITION 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Composition
  • 4.2. Mono Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Combination Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL TRAVEL VACCINES MARKET: BY DISEASE TYPE 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Disease Type
  • 5.2. Hepatitis A Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Hepatitis B Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.5. Diphtheria Pertussis Tetanus (DPT) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.6. Rabies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.7. Yellow Fever Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.8. Typhoid Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.9. Measles And Mumps Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.10. Meningococcal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.11. Other Disease Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL TRAVEL VACCINES MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Outbound Travel Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Domestic Travel Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL TRAVEL VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.2.1 By Composition
    • 7.2.2 By Disease Type
    • 7.2.3 By Application
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.3.1 By Composition
    • 7.3.2 By Disease Type
    • 7.3.3 By Application
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.4.1 By Composition
    • 7.4.2 By Disease Type
    • 7.4.3 By Application
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.5.1 By Composition
    • 7.5.2 By Disease Type
    • 7.5.3 By Application
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.6.1 By Composition
    • 7.6.2 By Disease Type
    • 7.6.3 By Application
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TRAVEL VACCINES INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 GSK Plc
    • 9.2.2 Sanofi
    • 9.2.3 Janssen Pharmaceuticals Inc
    • 9.2.4 Pfizer Inc
    • 9.2.5 CSL Ltd
    • 9.2.6 Qiagen N.V
    • 9.2.7 AstraZeneca
    • 9.2.8 F. Hoffmann-La Roche Ltd
    • 9.2.9 Abbott Laboratories
    • 9.2.10 Valneva Inc